S&P Futures
3,864.50 +16.25 (+0.42%) Dow Futures
31,150.00 +137.00 (+0.44%) Nasdaq Futures
11,935.75 +55.50 (+0.47%) Russell 2000 Futures
1,738.10 +9.50 (+0.55%) Crude Oil
98.85 +0.32 (+0.32%) Gold
1,740.60 +4.10 (+0.24%)
Theseus Pharmaceuticals, Inc. (THRX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 5.98 |
| Open | 5.95 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1100 |
| Day's Range | 5.95 - 6.70 |
| 52 Week Range | 4.86 - 24.54 |
| Volume | |
| Avg. Volume | 101,580 |
| Market Cap | 254.663M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.76 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.60 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for THRX
Related Research
- Theseus Pharmaceuticals, Inc.Daily – Vickers Top Buyers & Sellers for 10/15/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat9 months agoArgus Research
- Benzinga
HC Wainwright Sees Over 300% Upside In This Cancer-Focused Stock
HC Wainwright has initiated Theseus Pharmaceuticals Inc (NASDAQ: THRX) with a Buy rating and a price target of $22 (310% upside). The analysts see gastrointestinal stromal tumors (GISTs) treatment space reigniting with the entrance of a Theseus' pan-KIT inhibitor THE-630, with a high likelihood of 5L approval with earlier line potential. The analysts believe THE-630 can adequately tackle resistance in GIST by using dynamic molecular touchpoints that aim to ensure retention of inhibition. Related
- Barrons.com
Mereo BioPharm and Theseus Pharmaceuticals See Action From Activist Investors
Rubric Capital disclosed a large stake in Mereo BioPharm. Foresite Capital raised its stake in Theseus Pharmaceuticals.
- Simply Wall St.
Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
